Pharmaceutical

Merus gets grant for treatment of clec12a positive cancer with bispecific antibody

Discover a groundbreaking patent for treating CLEC12A positive cancer with bispecific antibodies. Learn about a unique dosing strategy to target cancer cells effectively while sparing hemopoietic stem cells.

May 1, 2024 - 00:00
Discover a groundbreaking patent for treating CLEC12A positive cancer with bispecific antibodies. Learn about a unique dosing strategy to target cancer cells effectively while sparing hemopoietic stem cells.
Read the original article

Tags:

Previous Article

Corcept Therapeutics gets grant for method of preparing compound of formula i

Next Article

Pacira BioSciences gets grant for method for treating spasticity in a patient’s ...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

CHMP recommends full marketing approval for Gilead Sciences’ Hepcludex

CHMP recommends full marketing approval for Gilead Scie...

May 6, 2023

STAT+: The inside story of how data integrity issues roiled a biotech seen as ‘Moderna 2.0’

STAT+: The inside story of how data integrity issues ro...

Jun 12, 2023

ALS advocates say criticism of new drugs misses bigger picture

ALS advocates say criticism of new drugs misses bigger ...

Sep 8, 2023